Metacrine Inc. (MTCR): Price and Financial Metrics


Metacrine Inc. (MTCR): $3.07

-0.05 (-1.60%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MTCR Stock Price Chart Interactive Chart >

Price chart for MTCR

MTCR Price/Volume Stats

Current price $3.07 52-week high $11.65
Prev. close $3.12 52-week low $2.59
Day low $3.02 Volume 192,600
Day high $3.17 Avg. volume 139,132
50-day MA $3.00 Dividend yield N/A
200-day MA $5.66 Market Cap 81.43M

Metacrine Inc. (MTCR) Company Bio


Metacrine, Inc. is a clinical-stage biopharmaceutical company that engages in the discovery and development of differentiated therapies for patients with liver and gastrointestinal diseases. Its farnesoid X receptor, or FXR, is central to modulating liver and GI diseases. The company was founded by Ronald M. Evans, Richard A. Heyman, and Michael Downes in 2014 and is headquartered in San Diego, CA.


MTCR Latest News Stream


Event/Time News Detail
Loading, please wait...

MTCR Latest Social Stream


Loading social stream, please wait...

View Full MTCR Social Stream

Latest MTCR News From Around the Web

Below are the latest news stories about Metacrine Inc that investors may wish to consider to help them evaluate MTCR as an investment opportunity.

Metacrine Achieves Full Enrollment for MET642 Phase 2a Trial in Patients With Nash

Exceeded enrollment target of 180 total patientsInterim data from the first 60 patients expected early in the fourth quarter of 2021Topline MET642 trial results from all patients are anticipated in the first half of 2022 SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that it has completed enrollment for its Phase 2a tr

Yahoo | September 9, 2021

Metacrine to Host Virtual R&D Day for Analysts and Investors on September 15, 2021

Featuring KOL and management discussions on the science of FXR agonists and the Company’s programs in NASH and IBD SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced it will host a virtual R&D Day for analysts and investors on Wednesday, September 15, 2021 at 12:00 p.m. ET. The event will showcase Metacrine’s programs in n

Yahoo | September 8, 2021

Metacrine to Present at H.C. Wainwright 23rd Annual Global Investment Conference

SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer, will present virtually at the H.C. Wainwright 23rd Annual Global Investment Conference at 7:00 a.m. ET on Monday, September 13, 2021. A webcast of the presentation will be available at https://investor

Yahoo | September 7, 2021

Metacrine Updates MET642 Clinical Development Milestone and Reports Second-Quarter 2021 Results

Interim data from the Phase 2a trial of MET642 in patients with NASH now expected early in the fourth quarter of 2021Topline results from a Phase 2a trial of MET409 in combination with empagliflozin in patients with NASH and type 2 diabetes on track to be reported in the fourth quarter of 2021 SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal disea

Yahoo | August 12, 2021

Metacrine to Present at 2021 Canaccord Genuity Growth Conference

SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer, will present virtually at the 2021 Canaccord Genuity Growth Conference at 12:30 p.m. ET on Thursday, August 12, 2021. A live webcast of the presentation will be available at https://investors.metacrine.

Yahoo | August 9, 2021

Read More 'MTCR' Stories Here

MTCR Price Returns

1-mo 9.25%
3-mo -21.28%
6-mo -56.14%
1-year -69.60%
3-year N/A
5-year N/A
YTD -60.94%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8204 seconds.